← Leaderboards
Paul Ruff
Wits Health Consortium (Pty), Ltd
$759,247
Attributed
$3,700,743
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2015–24$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,599,013 · 3
By mechanism
U54$5,898,270 · 1
R01$3,700,743 · 2
Top collaborators
- Judith S Jacobson11 shared
- Maureen Joffe11 shared
- Alfred I Neugut11 shared
- Carla J Chibwesha7 shared
- Blossom A Damania7 shared
- Dirk P Dittmer7 shared
- Yuri Fedoriw7 shared
- Herbert Cubasch6 shared
Most similar at Wits Health Consortium (Pty), Ltd
Same institution · by research overlap
- Maureen Joffe$759,247
- Neil A Martinson$7,090,642
- Michele Michele Ramsay$12,183,837
- Herbert Cubasch$331,878
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsUniversitiesResearch PersonnelAfrica South Of The SaharaSouth AfricaHospitalsAntiretroviral TherapyCollaborationsInsightSouth AfricanSurvival RateComorbidityProgramsWomanLow And Middle-Income CountriesFemaleReportingResourcesPrevalenceAchievementCancer TherapyCessation Of LifeMalignant Breast NeoplasmBreast Cancer Patient
Grant awards (18)
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,094,228
U54 · FY2024 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$345,761
R01 · FY2024 · CA
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,097,066
U54 · FY2023 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$347,160
R01 · FY2023 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$124,999
R01 · FY2023 · CA
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,101,859
U54 · FY2022 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$348,517
R01 · FY2022 · CA
Performance of different sample types for high-risk human papillomavirus testing and genotyping for the detection of high grade cervical intraepithelial neoplasia$125,000
U54 · FY2022 · CA
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,109,032
U54 · FY2021 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$474,837
R01 · FY2021 · CA
The road to recovery: An assessment of patient-reported quality of life among cancer survivors in Malawi.$190,625
U54 · FY2021 · CA
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa$1,180,460
U54 · FY2020 · CA
Novel predictors of survival among breast cancer patients with/without HIV in South Africa$349,996
R01 · FY2020 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$336,973
R01 · FY2019 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$342,373
R01 · FY2018 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$335,700
R01 · FY2017 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$344,783
R01 · FY2016 · CA
HIV's Effects on Breast Cancer Treatment and Outcomes in South Africa$349,644
R01 · FY2015 · CA